Recently, it was reported that SETD2 regulates the deposition of H3K36me3 by interacting with hnRNPL [38], and that SETD2 suppresses metastatic progression of prostate cancer by methylating EZH2 to lead its degradation [39]. Here, SETD2 is linked to prostate carcinoma.